company background image
AT2 logo

Atara Biotherapeutics DB:AT2 Stock Report

Last Price

€0.62

Market Cap

€55.9m

7D

-4.2%

1Y

-77.7%

Updated

19 Mar, 2024

Data

Company Financials +

Atara Biotherapeutics, Inc.

DB:AT2 Stock Report

Market Cap: €55.9m

AT2 Stock Overview

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States.

AT2 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Atara Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atara Biotherapeutics
Historical stock prices
Current Share PriceUS$0.62
52 Week HighUS$2.82
52 Week LowUS$0.18
Beta0.71
1 Month Change-12.38%
3 Month Change21.96%
1 Year Change-77.73%
3 Year Change-95.12%
5 Year Change-98.12%
Change since IPO-94.62%

Recent News & Updates

Recent updates

Shareholder Returns

AT2DE BiotechsDE Market
7D-4.2%-1.5%-0.4%
1Y-77.7%28.1%5.0%

Return vs Industry: AT2 underperformed the German Biotechs industry which returned 26% over the past year.

Return vs Market: AT2 underperformed the German Market which returned 6.2% over the past year.

Price Volatility

Is AT2's price volatile compared to industry and market?
AT2 volatility
AT2 Average Weekly Movement27.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: AT2's share price has been volatile over the past 3 months.

Volatility Over Time: AT2's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2012317Pascal Touchonhttps://www.atarabio.com

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.

Atara Biotherapeutics, Inc. Fundamentals Summary

How do Atara Biotherapeutics's earnings and revenue compare to its market cap?
AT2 fundamental statistics
Market cap€55.87m
Earnings (TTM)-€267.14m
Revenue (TTM)€4.18m

15.3x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AT2 income statement (TTM)
RevenueUS$4.54m
Cost of RevenueUS$5.73m
Gross Profit-US$1.18m
Other ExpensesUS$289.06m
Earnings-US$290.25m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.85
Gross Margin-26.07%
Net Profit Margin-6,390.31%
Debt/Equity Ratio0%

How did AT2 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.